EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Interaction between riluzole treatment and dietary glycemic index in the disease progression of amyotrophic lateral sclerosis

Ikjae Lee iD, Hiroshi Mitsumoto, Seonjoo Lee, Edward Kasarskis, Michael Rosenbaum, Pam Factor-Litvak, Jeri W Nieves

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.52294 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Ikjae Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Columbia University Irving Medical Center, New York, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Disease Progression, Glycemic Index, Neuroprotective Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We examined whether riluzole treatment modifies the associations between the dietary glycemic index (GI) and load (GL) and disease progression in amyotrophic lateral sclerosis (ALS).

Methods

Sporadic ALS patients in the Multicenter Cohort Study of Oxidative Stress who completed a baseline food frequency questionnaire were included ( n = 304). Interactions between baseline riluzole treatment and GI/GL on functional decline and tracheostomy‐free survival were examined using linear regression and Cox proportional hazard models adjusted for covariates. Age, sex, disease duration, diagnostic certainty, body mass index, bulbar onset, revised ALS functional rating scale (ALSFRS‐r) total score, and forced vital capacity, from baseline were included as covariates.

Results

Baseline higher GI and GL were associated with less decline of ALSFRS‐r total score at 3‐month follow‐up in the riluzole treatment group (RTG) but not in the no‐riluzole group (NRG). When quartile groups were used, GI second [β = −1.9, 95% CI (−4.1, −0.2), p = 0.07], third [β = −3.0, 95% CI (−5.1, −0.8), p < 0.01] and fourth [β = −2.2, 95% CI (−4.3, −0.01), p < 0.05] quartile groups were associated with less ALSFRS‐r decline at 3‐months compared to the first quartile group (GI < 47.2) among the RTG. Similarly, GL fourth quartile group (GL > 109.5) was associated with less ALSFRS‐r decline at 3 months compared to the first quartile group [β = −2.6, 95% CI (−4.7, −0.5), p < 0.05] among the RTG. In NRG, no statistically significant differences in ALSFRS‐r decline were found among GI/GL quartile groups.

Interpretation

High dietary GI and GL are associated with a slower functional decline only among ALS patients taking riluzole.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisDisease ProgressionGlycemic IndexNeuroprotective AgentsRiluzoleAgedFemaleHumansMaleMiddle AgedCohort Studies

Substanzen

Neuroprotective AgentsRiluzole

Autor:innen und Institutionen

  • Department of Neurology, Columbia University Irving Medical Center, New York, USA.
  • Department of Biostatistics and Psychiatry, Columbia University, New York, USA.
  • Department of Neurology, University of Kentucky, Lexington, Kentucky, USA.
  • Departments of Pediatrics and Medicine, Columbia University Irving Medical Center, New York, USA.
  • Department of Epidemiology, Columbia University Mailman School of Public Health, New York, USA.

ORCID-Profile: Ikjae Lee

Förderung

  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Lee, I., Mitsumoto, H., Lee, S., Kasarskis, E., Rosenbaum, M., Factor-Litvak, P., & Nieves, J. W. (2025). Interaction between riluzole treatment and dietary glycemic index in the disease progression of amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52294

Vancouver

Lee I, Mitsumoto H, Lee S, Kasarskis E, Rosenbaum M, Factor-Litvak P, et al. Interaction between riluzole treatment and dietary glycemic index in the disease progression of amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.52294

BibTeX
@article{Lee2025,
  author = {Lee, Ikjae and Mitsumoto, Hiroshi and Lee, Seonjoo and Kasarskis, Edward and Rosenbaum, Michael and Factor-Litvak, Pam and Nieves, Jeri W},
  title = {Interaction between riluzole treatment and dietary glycemic index in the disease progression of amyotrophic lateral sclerosis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.52294}
}
Kostenlos starten →